(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the US session.

The three biggest winners today are Hostess Brands, Rubius Therapeutics, and Stitch Fix.

The three biggest losers today are ToughBuilt Industries, Sonoma Pharmaceuticals, and Secoo Holding Limited.

Winners today

1. Hostess Brands (TWNKW) – 41.59%

Hostess Brands, Inc., a packaged food company, develops, manufactures, markets, sells, and distributes fresh sweet baked goods in the United States. It primarily offer a range of snack cakes, donuts, sweet rolls, breakfast pastries, snack pies, and related products. The company operates in two segments, Sweet Baked Goods and In-Store Bakery. The Sweet Baked Goods segment offers fresh and frozen sweet baked goods and bread products under the Hostess, Dolly Madison, Cloverhill, and Big Texas brands, as well as store branded products. The In-Store Bakery segment primarily provides Superior on Main branded eclairs, madeleines, brownies, and iced cookies in the bakery section of grocery and club stores. The company was formerly known as Gores Holdings, Inc. and changed its name to Hostess Brands, Inc. in November 2016. Hostess Brands, Inc. was founded in 1919 and is based in Lenexa, Kansas.

NASDAQ ended the session with Hostess Brands jumping 41.59% to $3.20 on Wednesday, after five successive sessions in a row of losses. NASDAQ slid 2.43% to $12,821.22, after two sequential sessions in a row of gains, on what was an all-around down trend exchanging session today.

PE Ratio

Hostess Brands has a trailing twelve months price to earnings ratio of 5.15. Meaning, the purchaser of the share is investing $5.15 for every dollar of annual earnings.

Yearly Top and Bottom Value

Hostess Brands’s stock is valued at $3.20 at 17:32 EST, way under its 52-week high of $4.02 and way above its 52-week low of $1.12.

Volume

Today’s last reported volume for Hostess Brands is 29718 which is 70.4% below its average volume of 100427.

More news about Hostess Brands.

2. Rubius Therapeutics (RUBY) – 28.65%

Rubius Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing RTX-240 and RTX-224 for the treatment of solid tumors cancer; and RTX-aAPC to treat cancers. It is also developing RTX-321 for the treatment of HPV-positive tumors; and RTX-T1D for treating type 1 diabetes. The company was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.

NASDAQ ended the session with Rubius Therapeutics rising 28.65% to $0.02 on Wednesday while NASDAQ slid 2.43% to $12,821.22.

Earnings Per Share

As for profitability, Rubius Therapeutics has a trailing twelve months EPS of $-1.99.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -185.31%.

Moving Average

Rubius Therapeutics’s value is way higher than its 50-day moving average of $0.02 and way under its 200-day moving average of $0.05.

Yearly Top and Bottom Value

Rubius Therapeutics’s stock is valued at $0.02 at 17:32 EST, way below its 52-week high of $0.42 and way higher than its 52-week low of $0.00.

More news about Rubius Therapeutics.

3. Stitch Fix (SFIX) – 15.36%

Stitch Fix, Inc. sells a range of apparel, shoes, and accessories through its Website and mobile application in the United States. It offers denim, dresses, blouses, skirts, shoes, jewelry, and handbags for men, women, and kids under the Stitch Fix brand. The company was formerly known as rack habit inc. and changed its name to Stitch Fix, Inc. in October 2011. Stitch Fix, Inc. was incorporated in 2011 and is headquartered in San Francisco, California.

NASDAQ ended the session with Stitch Fix rising 15.36% to $3.68 on Wednesday while NASDAQ slid 2.43% to $12,821.22.

Earnings Per Share

As for profitability, Stitch Fix has a trailing twelve months EPS of $-1.5.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -60.35%.

More news about Stitch Fix.

4. Revolution Medicines (RVMD) – 14.52%

Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

NASDAQ ended the session with Revolution Medicines rising 14.52% to $21.02 on Wednesday, following the last session’s upward trend. NASDAQ slid 2.43% to $12,821.22, after two sequential sessions in a row of gains, on what was an all-around bearish trend trading session today.

Earnings Per Share

As for profitability, Revolution Medicines has a trailing twelve months EPS of $-3.13.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -41.44%.

Yearly Top and Bottom Value

Revolution Medicines’s stock is valued at $21.02 at 17:32 EST, way below its 52-week high of $35.60 and way above its 52-week low of $15.44.

Growth Estimates Quarters

The company’s growth estimates for the ongoing quarter and the next is a negative 16.1% and a negative 50.8%, respectively.

Moving Average

Revolution Medicines’s value is way below its 50-day moving average of $29.64 and way under its 200-day moving average of $26.37.

Sales Growth

Revolution Medicines’s sales growth is negative 77.7% for the present quarter and negative 95.1% for the next.

More news about Revolution Medicines.

5. Seanergy Maritime Holdings Corp (SHIPW) – 10%

NASDAQ ended the session with Seanergy Maritime Holdings Corp rising 10% to $0.03 on Wednesday while NASDAQ slid 2.43% to $12,821.22.

PE Ratio

Seanergy Maritime Holdings Corp has a trailing twelve months price to earnings ratio of 0.21. Meaning, the purchaser of the share is investing $0.21 for every dollar of annual earnings.

Yearly Top and Bottom Value

Seanergy Maritime Holdings Corp’s stock is valued at $0.03 at 17:32 EST, under its 52-week high of $0.03 and higher than its 52-week low of $0.03.

More news about Seanergy Maritime Holdings Corp.

6. Cassava Sciences (SAVA) – 9.25%

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.

NASDAQ ended the session with Cassava Sciences rising 9.25% to $14.77 on Wednesday, following the last session’s upward trend. NASDAQ dropped 2.43% to $12,821.22, after two consecutive sessions in a row of gains, on what was an all-around bearish trend exchanging session today.

Earnings Per Share

As for profitability, Cassava Sciences has a trailing twelve months EPS of $-2.19.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -45.28%.

Moving Average

Cassava Sciences’s value is way under its 50-day moving average of $17.94 and way under its 200-day moving average of $23.11.

Growth Estimates Quarters

The company’s growth estimates for the ongoing quarter and the next is a negative 51% and a negative 89.4%, respectively.

More news about Cassava Sciences.

7. Deutsche Bank (DB) – 8%

Deutsche Bank Aktiengesellschaft, operates as a stock corporation, engages in the provision of corporate and investment banking, and asset management products and services to private clients, corporate entities, and institutional clients worldwide. Its Corporate Bank segment provides cash management, trade finance and lending, trust and agency, foreign exchange, and securities services, as well as risk management solutions. The company's Investment Bank segment offers debt origination, merger and acquisitions, and equity advisory services. Its Private Bank segment provides payment and account services, and credit and deposit products, as well as investment advice products, such as environmental, social, and governance products. This segment also provides banking, wealth management services, postal and parcel services; and offers support in planning, managing and investing wealth, financing personal and business interests, and servicing institutional and corporate needs. The company's Asset Management segment provides investment solutions, such as alternative investments, which include real estate, infrastructure, private equity, liquid real assets, and sustainable investments; and various other services, including insurance and pension solutions, asset liability management, portfolio management solutions, and asset allocation advisory to individuals and institutions. Deutsche Bank Aktiengesellschaft was founded in 1870 and is based in Frankfurt am Main, Germany.

NYSE ended the session with Deutsche Bank jumping 8% to $10.86 on Wednesday, following the last session’s downward trend. NYSE fell 0.74% to $14,914.12, following the last session’s upward trend on what was a somewhat negative trend exchanging session today.

Earnings Per Share

As for profitability, Deutsche Bank has a trailing twelve months EPS of $2.43.

PE Ratio

Deutsche Bank has a trailing twelve months price to earnings ratio of 4.47. Meaning, the purchaser of the share is investing $4.47 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.74%.

Volatility

Deutsche Bank’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.59%, a negative 0.26%, and a positive 1.29%.

Deutsche Bank’s highest amplitude of average volatility was 0.86% (last week), 1.51% (last month), and 1.29% (last quarter).

Revenue Growth

Year-on-year quarterly revenue growth grew by 9.2%, now sitting on 26.85B for the twelve trailing months.

Volume

Today’s last reported volume for Deutsche Bank is 5394350 which is 148.55% above its average volume of 2170300.

Dividend Yield

As maintained by Morningstar, Inc., the next dividend payment is on May 17, 2023, the estimated forward annual dividend rate is 0.32 and the estimated forward annual dividend yield is 3.14%.

More news about Deutsche Bank.

8. Schrodinger (SDGR) – 7.59%

Schrödinger, Inc., together with its subsidiaries, provides physics-based software platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on selling its software for drug discovery in the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.

NASDAQ ended the session with Schrodinger jumping 7.59% to $23.66 on Wednesday while NASDAQ fell 2.43% to $12,821.22.

Earnings Per Share

As for profitability, Schrodinger has a trailing twelve months EPS of $0.84.

PE Ratio

Schrodinger has a trailing twelve months price to earnings ratio of 28.17. Meaning, the purchaser of the share is investing $28.17 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.02%.

Growth Estimates Quarters

The company’s growth estimates for the present quarter is a negative 30.4% and positive 13.2% for the next.

Moving Average

Schrodinger’s worth is way under its 50-day moving average of $30.61 and way under its 200-day moving average of $32.31.

More news about Schrodinger.

9. Scienjoy Holding Corporation (SJ) – 7.5%

Scienjoy Holding Corporation provides mobile live streaming platforms in the People's Republic of China. It focuses on interactive show live streaming from broadcasters to users. The company's platforms enable users to view and interact with broadcasters through online chat, virtual items, and playing games. As of December 31, 2021, it had 840,640 paying users and 288,898 active broadcasters. The company operates four live streaming platforms under the Showself Live Streaming, Lehai Live Streaming, Haixiu Live Streaming, BeeLive Live Stream names. It also offers technical development and advisory services. The company was founded in 2011 and is based in Beijing, the People's Republic of China. Scienjoy Holding Corporation is a subsidiary of Lavacano Holdings Limited.

NASDAQ ended the session with Scienjoy Holding Corporation jumping 7.5% to $3.01 on Wednesday, following the last session’s upward trend. NASDAQ fell 2.43% to $12,821.22, after two consecutive sessions in a row of gains, on what was an all-around bearish trend trading session today.

Earnings Per Share

As for profitability, Scienjoy Holding Corporation has a trailing twelve months EPS of $0.39.

PE Ratio

Scienjoy Holding Corporation has a trailing twelve months price to earnings ratio of 7.72. Meaning, the purchaser of the share is investing $7.72 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.48%.

Revenue Growth

Year-on-year quarterly revenue growth declined by 28.3%, now sitting on 1.65B for the twelve trailing months.

Volume

Today’s last reported volume for Scienjoy Holding Corporation is 15314 which is 91.75% below its average volume of 185635.

Yearly Top and Bottom Value

Scienjoy Holding Corporation’s stock is valued at $3.01 at 17:32 EST, way below its 52-week high of $4.80 and way higher than its 52-week low of $1.50.

More news about Scienjoy Holding Corporation.

10. Sol-Gel Technologies Ltd. (SLGL) – 7.14%

Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris; Epsolay, a once-daily topical cream that has completed Phase III clinical trials for the treatment of papulopustular rosacea; SGT-210, which is in Phase I clinical trial for the treatment of palmoplantar keratoderma; and Erlotinib, Tapinarof, and roflumilast to treat psoriasis and other medical conditions. It is also involved in the development of generic topical dermatological drug products. The company has collaboration with Perrigo. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.

NASDAQ ended the session with Sol-Gel Technologies Ltd. rising 7.14% to $1.50 on Wednesday, following the last session’s upward trend. NASDAQ slid 2.43% to $12,821.22, after two successive sessions in a row of gains, on what was an all-around negative trend exchanging session today.

Earnings Per Share

As for profitability, Sol-Gel Technologies Ltd. has a trailing twelve months EPS of $-1.03.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -52.48%.

More news about Sol-Gel Technologies Ltd..

Losers Today

1. ToughBuilt Industries (TBLTW) – -70.24%

NASDAQ ended the session with ToughBuilt Industries falling 70.24% to $0.01 on Wednesday, following the last session’s upward trend. NASDAQ fell 2.43% to $12,821.22, after two consecutive sessions in a row of gains, on what was an all-around down trend trading session today.

More news about ToughBuilt Industries.

2. Sonoma Pharmaceuticals (SNOA) – -26.33%

Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, and internationally. The company offers Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; Celacyn gel, a HOCl-based topical prescription product indicated to promote efficient healing through the management of new and old scars; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis. It also provides Acuicyn, a HOCl-based product indicated to relieve itch and inflammation while helping to keep areas around the eye clean; and Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a wide range of pathogens, as well as antibiotic-resistant strains that slow the natural healing of wounds. In addition, the company offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; Microdacyn60 oral care solution for the treatment of mouth and throat infections; MucoClyns for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns, and body surfaces; Endocyn root canal irrigation solutions; Pediacyn atopic dermatitis hydrogel; Ocucyn eyelid and eyelash cleanser; Gramaderm for the treatment of topical mild to moderate acne; Nanocyn, a hospital-grade disinfectant; and Sinudox for nasal irrigation. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Woodstock, Georgia.

NASDAQ ended the session with Sonoma Pharmaceuticals falling 26.33% to $0.38 on Wednesday while NASDAQ fell 2.43% to $12,821.22.

Earnings Per Share

As for profitability, Sonoma Pharmaceuticals has a trailing twelve months EPS of $-1.52.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -74.76%.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Sonoma Pharmaceuticals’s EBITDA is -2.12.

Revenue Growth

Year-on-year quarterly revenue growth declined by 14%, now sitting on 12.72M for the twelve trailing months.

Volume

Today’s last reported volume for Sonoma Pharmaceuticals is 241267 which is 839.69% above its average volume of 25675.

More news about Sonoma Pharmaceuticals.

3. Secoo Holding Limited (SECO) – -18.92%

Secoo Holding Limited, through its subsidiaries, operates an integrated online and offline shopping platform in the People's Republic of China, Hong Kong, and internationally. It provides upscale brand products and services, including handbags, watches, clothing, footwear, jewelry and accessories, cosmetics and skincare, home accessories, sportswear, home goods, fine food and beverage products, arts, 3C electronic devices, and Chinese original products, as well as lifestyle services through its website, mobile applications, and offline experience centers. The company also offers its website as a marketplace to third party merchants to facilitate their sales of upscale products and services. Secoo Holding Limited was incorporated in 2011 and is headquartered in Beijing, China.

NASDAQ ended the session with Secoo Holding Limited falling 18.92% to $0.83 on Wednesday, after three sequential sessions in a row of losses. NASDAQ fell 2.43% to $12,821.22, after two consecutive sessions in a row of gains, on what was an all-around bearish trend exchanging session today.

Earnings Per Share

As for profitability, Secoo Holding Limited has a trailing twelve months EPS of $-22.12.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -84.14%.

Revenue Growth

Year-on-year quarterly revenue growth declined by 23.7%, now sitting on 2.77B for the twelve trailing months.

More news about Secoo Holding Limited.

4. SiNtx Technologies (SINT) – -16.9%

Sintx Technologies, Inc., an advanced materials company, engages in the research, development, and commercialization of medical devices manufactured with silicon nitride for biomedical, industrial, and antipathogenic applications primarily in the United States. The company provides solid and porous silicon nitride; silicon nitrite powder; and silicon nitride coating products, as well as silicon nitride composite materials and polyetherketoneketone. The company was formerly known as Amedica Corporation. Sintx Technologies, Inc. was incorporated in 1996 and is headquartered in Salt Lake City, Utah.

NASDAQ ended the session with SiNtx Technologies dropping 16.9% to $0.44 on Wednesday while NASDAQ dropped 2.43% to $12,821.22.

Earnings Per Share

As for profitability, SiNtx Technologies has a trailing twelve months EPS of $-41.1.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -72.93%.

Moving Average

SiNtx Technologies’s worth is way under its 50-day moving average of $0.86 and way under its 200-day moving average of $2.26.

Earnings Before Interest, Taxes, Depreciation, and Amortization

SiNtx Technologies’s EBITDA is 2.44.

Sales Growth

SiNtx Technologies’s sales growth is 33.8% for the present quarter and negative 16.3% for the next.

More news about SiNtx Technologies.

5. Canopy Growth (CGC) – -13.55%

Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in Canada, the United States, and Germany. It operates through two segments, Global Cannabis and Other Consumer Products. The company's products include dried cannabis flower, extracts and concentrates, beverages, gummies, and vapes. It offers its products under the Tweed, 7ACRES, 7ACRES Craft Collective, DOJA, Ace Valley, Quatreau, Deep Space, First + Free, Surity Pro, Spectrum Therapeutics, Vert, Tokyo Smoke, Twd, Martha Stewart CBD, DNA Genetics, BioSteel, Storz & Bickel, This Works, HiWay, Simple Stash, Whisl, and Truverra brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation was incorporated in 2009 and is headquartered in Smiths Falls, Canada.

NASDAQ ended the session with Canopy Growth falling 13.55% to $0.54 on Wednesday, following the last session’s upward trend. NASDAQ slid 2.43% to $12,821.22, after two successive sessions in a row of gains, on what was an all-around negative trend exchanging session today.

Earnings Per Share

As for profitability, Canopy Growth has a trailing twelve months EPS of $-1.39.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -99.56%.

Moving Average

Canopy Growth’s worth is way below its 50-day moving average of $0.72 and way below its 200-day moving average of $1.28.

Volatility

Canopy Growth’s last week, last month’s, and last quarter’s current intraday variation average was a negative 6.53%, a negative 3.35%, and a positive 9.36%.

Canopy Growth’s highest amplitude of average volatility was 6.53% (last week), 5.70% (last month), and 9.36% (last quarter).

Previous days news about Canopy Growth

• Here's why canopy growth corporation (cgc) fell more than broader market. According to Zacks on Monday, 23 October, "The investment community will be paying close attention to the earnings performance of Canopy Growth Corporation in its upcoming release. ", "It is also important to note the recent changes to analyst estimates for Canopy Growth Corporation. "

More news about Canopy Growth.

6. Sonnet BioTherapeutics Holdings (SONN) – -12.14%

Sonnet BioTherapeutics Holdings, Inc., a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead candidate is SON-1010, a fully human version of interleukin 12 for the treatment non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6 for chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy. It has a license agreement with New Life Therapeutics PTE, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin 6. Sonnet BioTherapeutics Holdings, Inc. is based in Princeton, New Jersey.

NASDAQ ended the session with Sonnet BioTherapeutics Holdings falling 12.14% to $1.81 on Wednesday, after five successive sessions in a row of losses. NASDAQ dropped 2.43% to $12,821.22, after two consecutive sessions in a row of gains, on what was an all-around bearish trend trading session today.

Earnings Per Share

As for profitability, Sonnet BioTherapeutics Holdings has a trailing twelve months EPS of $-55.66.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -1080.24%.

Yearly Top and Bottom Value

Sonnet BioTherapeutics Holdings’s stock is valued at $1.81 at 17:32 EST, way below its 52-week high of $66.00 and higher than its 52-week low of $1.81.

Volume

Today’s last reported volume for Sonnet BioTherapeutics Holdings is 85799 which is 19.73% above its average volume of 71660.

Revenue Growth

Year-on-year quarterly revenue growth declined by 40.6%, now sitting on 173.3k for the twelve trailing months.

More news about Sonnet BioTherapeutics Holdings.

7. 3D Systems (DDD) – -12.13%

3D Systems Corporation provides 3D printing and digital manufacturing solutions in the Americas, Europe, the Middle East, Africa, the Asia Pacific, and internationally. The company offers 3D printers technologies, such as stereolithography, selective laser sintering, direct metal printing, multi jet printing, color jet printing, polymer extrusion, and extrusion and SLA based bioprinting that transform digital data input generated by 3D design software, computer aided design (CAD) software, or other 3D design tools into printed parts. It also develops, blends, and markets various print materials, such as plastic, nylon, metal, composite, elastomeric, wax, polymeric dental materials, and biocompatible materials. In addition, the company provides digital design tools, including software, scanners, and haptic devices, as well as solutions for product design, simulation, mold and die design, 3D scan-to-print, reverse engineering, production machining, metrology, and inspection and manufacturing workflows under the Geomagic brand. Further, it offers 3D Sprint and 3DXpert, a proprietary software to prepare and optimize CAD data and manage the additive manufacturing processes, which provides automated support building and placement, build platform management, print simulation, and print queue management; and Bioprint Pro, a software solution that allows researchers to design and bioprint repeatable experiments. Additionally, the company provides maintenance and training services; manufacturing services; and software and precision healthcare services. It primarily serves companies and small and midsize businesses in medical, dental, automotive, aerospace, durable goods, government, defense, technology, jewelry, electronic, education, consumer goods, energy, biotechnology, and other industries through direct sales force, channel partners, and appointed distributors. 3D Systems Corporation was founded in 1986 and is headquartered in Rock Hill, South Carolina.

NYSE ended the session with 3D Systems falling 12.13% to $3.88 on Wednesday while NYSE dropped 0.74% to $14,914.12.

Earnings Per Share

As for profitability, 3D Systems has a trailing twelve months EPS of $-0.94.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -16.22%.

More news about 3D Systems.

8. 3D Systems (DDD) – -12.13%

3D Systems Corporation provides 3D printing and digital manufacturing solutions in the Americas, Europe, the Middle East, Africa, the Asia Pacific, and internationally. The company offers 3D printers technologies, such as stereolithography, selective laser sintering, direct metal printing, multi jet printing, color jet printing, polymer extrusion, and extrusion and SLA based bioprinting that transform digital data input generated by 3D design software, computer aided design (CAD) software, or other 3D design tools into printed parts. It also develops, blends, and markets various print materials, such as plastic, nylon, metal, composite, elastomeric, wax, polymeric dental materials, and biocompatible materials. In addition, the company provides digital design tools, including software, scanners, and haptic devices, as well as solutions for product design, simulation, mold and die design, 3D scan-to-print, reverse engineering, production machining, metrology, and inspection and manufacturing workflows under the Geomagic brand. Further, it offers 3D Sprint and 3DXpert, a proprietary software to prepare and optimize CAD data and manage the additive manufacturing processes, which provides automated support building and placement, build platform management, print simulation, and print queue management; and Bioprint Pro, a software solution that allows researchers to design and bioprint repeatable experiments. Additionally, the company provides maintenance and training services; manufacturing services; and software and precision healthcare services. It primarily serves companies and small and midsize businesses in medical, dental, automotive, aerospace, durable goods, government, defense, technology, jewelry, electronic, education, consumer goods, energy, biotechnology, and other industries through direct sales force, channel partners, and appointed distributors. 3D Systems Corporation was founded in 1986 and is headquartered in Rock Hill, South Carolina.

NYSE ended the session with 3D Systems sliding 12.13% to $3.88 on Wednesday, following the last session’s upward trend. NYSE slid 0.74% to $14,914.12, following the last session’s upward trend on what was a somewhat down trend exchanging session today.

Earnings Per Share

As for profitability, 3D Systems has a trailing twelve months EPS of $-0.94.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -16.22%.

Yearly Top and Bottom Value

3D Systems’s stock is valued at $3.88 at 17:32 EST, way under its 52-week high of $12.67 and higher than its 52-week low of $3.81.

More news about 3D Systems.

9. MarketAxess Holdings (MKTX) – -11.87%

MarketAxess Holdings Inc., together with its subsidiaries, operates an electronic trading platform for institutional investor and broker-dealer companies worldwide. It offers the access to liquidity in the U.S. investment-grade bonds, U.S. high-yield bonds, and U.S. Treasuries, as well as municipal bonds, emerging market debts, Eurobonds, and other fixed-income securities. The company, through its Open Trading protocols, executes bond trades between and among institutional investor and broker-dealer clients in an all-to-all anonymous trading environment for corporate bonds. It also offers trading-related products and services, including composite+ pricing and other market data products to assist clients with trading decisions; auto-execution and other execution services for clients requiring specialized workflow solutions; connectivity solutions that facilitate straight-through processing; and technology services to optimize trading environments. In addition, the company provides various pre-and post-trade services, such as trade matching, trade publication, regulatory transaction reporting, and market and reference data across a range of fixed-income and other products. MarketAxess Holdings Inc. was incorporated in 2000 and is headquartered in New York, New York.

NASDAQ ended the session with MarketAxess Holdings dropping 11.87% to $207.92 on Wednesday, following the last session’s upward trend. NASDAQ slid 2.43% to $12,821.22, after two sequential sessions in a row of gains, on what was an all-around down trend trading session today.

Earnings Per Share

As for profitability, MarketAxess Holdings has a trailing twelve months EPS of $6.7.

PE Ratio

MarketAxess Holdings has a trailing twelve months price to earnings ratio of 31.03. Meaning, the purchaser of the share is investing $31.03 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 23.27%.

Volume

Today’s last reported volume for MarketAxess Holdings is 677945 which is 58.23% above its average volume of 428448.

More news about MarketAxess Holdings.

10. TRACON Pharmaceuticals (TCON) – -10.82%

TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of soft tissue sarcoma; and YH001, an investigational humanized CTLA-4 IgG1 monoclonal antibody for the treatment of various cancer indications. The company's clinical stage products also include TRC102, a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, and in Phase I clinical trial to treat solid tumors and lymphomas, lung cancer, and glioblastoma; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309; Case Western Reserve University for the development of TRC102; and cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California.

NASDAQ ended the session with TRACON Pharmaceuticals dropping 10.82% to $0.17 on Wednesday, following the last session’s upward trend. NASDAQ fell 2.43% to $12,821.22, after two successive sessions in a row of gains, on what was an all-around bearish trend exchanging session today.

Earnings Per Share

As for profitability, TRACON Pharmaceuticals has a trailing twelve months EPS of $-1.14.

Volume

Today’s last reported volume for TRACON Pharmaceuticals is 154943 which is 81.37% below its average volume of 831948.

Moving Average

TRACON Pharmaceuticals’s value is way under its 50-day moving average of $0.21 and way under its 200-day moving average of $0.86.

Yearly Top and Bottom Value

TRACON Pharmaceuticals’s stock is valued at $0.17 at 17:32 EST, way below its 52-week high of $2.19 and way higher than its 52-week low of $0.13.

More news about TRACON Pharmaceuticals.

Stay up to date with our winners and losers daily report